These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20127278)

  • 1. The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects.
    Yao L; Qiu LX; Yu L; Yang Z; Yu XJ; Zhong Y; Hu XC; Yu L
    Breast Cancer Res Treat; 2010 Aug; 123(1):227-31. PubMed ID: 20127278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects.
    Zhang J; Qiu LX; Leaw SJ; Hu XC; Chang JH
    Med Oncol; 2011 Sep; 28(3):655-60. PubMed ID: 20354818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
    Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
    World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between XPD Asp312Asn polymorphism and risk of head and neck cancer: a meta-analysis based on 7,122 subjects.
    Hu YY; Yuan H; Jiang GB; Chen N; Wen L; Leng WD; Zeng XT; Niu YM
    PLoS One; 2012; 7(4):e35220. PubMed ID: 22536360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis.
    Duan XL; Gong H; Zeng XT; Ni XB; Yan Y; Chen W; Liu GL
    Asian Pac J Cancer Prev; 2012; 13(7):3299-303. PubMed ID: 22994751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.
    Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X
    Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.
    Zhang Y; Ding D; Wang X; Zhu Z; Huang M; He X
    Int J Colorectal Dis; 2011 Oct; 26(10):1257-64. PubMed ID: 21541661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.
    Ma Q; Qi C; Tie C; Guo Z
    Gene; 2013 Nov; 530(2):309-14. PubMed ID: 23973729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.
    Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY
    Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.
    Zhou JY; He LW; Liu J; Yu HL; Wei M; Ma WL; Shi R
    Asian Pac J Cancer Prev; 2014; 15(21):9347-53. PubMed ID: 25422223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk: a meta-analysis.
    Chen B; Zhou Y; Yang P; Wu XT
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):939-46. PubMed ID: 20981556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.
    Yin QH; Liu C; Hu JB; Meng RR; Li L; Wang YJ
    Asian Pac J Cancer Prev; 2013; 14(1):231-6. PubMed ID: 23534729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility.
    Wen F; Zhao Z; Liu C; Yin Q; Weng J; Wang Y; Ma Y
    Tumour Biol; 2014 Apr; 35(4):2959-65. PubMed ID: 24234258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer.
    Pabalan N; Francisco-Pabalan O; Sung L; Jarjanazi H; Ozcelik H
    Breast Cancer Res Treat; 2010 Nov; 124(2):531-41. PubMed ID: 20379847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of two common xeroderma pigmentosum group D (XPD) gene polymorphisms on risk of prostate cancer.
    Mi Y; Zhang L; Feng N; Wu S; You X; Shao H; Dai F; Peng T; Qin F; Zou J; Zhu L
    PLoS One; 2012; 7(9):e44756. PubMed ID: 23028604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis.
    Wang M; Gu D; Zhang Z; Zhou J; Zhang Z
    J Toxicol Environ Health A; 2009; 72(11-12):698-705. PubMed ID: 19492231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the ERCC2 Asp312Asn polymorphism and risk of cancer.
    Xiao F; Pu J; Wen Q; Huang Q; Zhang Q; Huang B; Huang S; Lan A; Zhang Y; Li J; Zhao D; Shen J; Wu H; He Y; Li H; Yang X
    Oncotarget; 2017 Jul; 8(29):48488-48506. PubMed ID: 28489582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in XPD and hOGG1 and prostate cancer risk: a meta-analysis.
    Zhu S; Zhang H; Tang Y; Wang J
    Urol Int; 2012; 89(2):233-40. PubMed ID: 22890093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis.
    Wu Y; Lu ZP; Zhang JJ; Liu DF; Shi GD; Zhang C; Qin ZQ; Zhang JZ; He Y; Wu PF; Miao Y; Jiang KR
    Oncotarget; 2017 Jul; 8(30):50124-50132. PubMed ID: 28223548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex association between ERCC2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: a meta-analysis.
    Wu Y; Yang Y
    Tumour Biol; 2014 Jun; 35(6):5245-57. PubMed ID: 24504678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.